Regeneron Surges 2.8% on Groundbreaking Myeloma Trial Data: Is This the Catalyst for a New Bull Run?

Summary
• Regeneron (REGN) rockets 2.84% to $711.96, hitting an intraday high of $717.88
• Lynozyfic trial data shows 100% residual disease eradication in 18 myeloma patients
• Options frenzy: 2025-12-19 $720 call options surge 96.46% in turnover
• Biotech sector gains momentum as Amgen (AMGN) climbs 0.65%

Regeneron’s shares are surging on a seismic breakthrough in its Lynozyfic trial for multiple myeloma, with the stock trading near its 52-week high. The biotech giant’s antibody therapy demonstrated unprecedented efficacy in eradicating residual cancer cells, sparking a buying frenzy. With options volatility spiking and technical indicators flashing bullish signals, investors are scrambling to position for a potential breakout.

Lynozyfic’s Myeloma Miracle Ignites Biotech Optimism
Regeneron’s 2.84% intraday rally is directly tied to its mid-stage trial results for Lynozyfic, a dual-target antibody therapy for multiple myeloma. The drug, approved in July, showed 100% eradication of residual cancer cells in 18 patients after six cycles, potentially eliminating the need for bone marrow transplants. Lead researcher Dr. C. Ola Landgren emphasized the therapy’s potential to extend remission durations, with some patients possibly achieving permanent remission. This data, presented at the American Society of Hematology, has repositioned Lynozyfic as a paradigm-shifting treatment, driving immediate demand for the stock.

Biotech Sector Gains Momentum as Amgen Trails Behind
The biotech sector is showing renewed vigor, with Amgen (AMGN) rising 0.65% despite trailing Regeneron’s performance. While Amgen’s focus on established therapies like Repatha and Otezla provides stability, Regeneron’s breakthrough in myeloma treatment highlights the sector’s innovation potential. The contrast underscores a shift in investor sentiment toward high-impact, first-in-class therapies over incremental improvements in existing drug pipelines.

Options and ETFs to Capitalize on Regeneron’s Breakout Momentum
• 200-day MA: $598.90 (well below current price)
• RSI: 41.89 (oversold territory)
• MACD: 18.27 (bullish divergence)
• Bollinger Bands: Price near upper band at $795.76
• Support/Resistance: 30D support at $653.49, 200D support at $556.09

Regeneron’s technicals suggest a continuation of its upward trajectory, with the RSI indicating oversold conditions and the MACD showing bullish momentum. The stock is trading near its 52-week high of $790.98, with the upper Bollinger Band at $795.76 acting as a key resistance level. Aggressive bulls should monitor a break above $717.88 (intraday high) for a potential run to $730.

Top Options Picks:
1. REGN20251219C720
• Strike: $720, Expiry: 2025-12-19
• IV: 30.66% (moderate)
• Delta: 0.4295 (moderate sensitivity)
• Theta: -1.783 (high time decay)
• Gamma: 0.01087 (high sensitivity to price swings)
• Turnover: 4,005 (liquid)
• Leverage: 64.14% (high)
• Payoff at 5% upside: $35.80
This call option offers a compelling risk/reward profile with high leverage and gamma, ideal for capitalizing on a short-term breakout. The moderate IV and high liquidity ensure efficient entry/exit.
2. REGN20251219C725
• Strike: $725, Expiry: 2025-12-19
• IV: 26.19% (reasonable)
• Delta: 0.3536 (moderate)
• Theta: -1.4656 (high decay)
• Gamma: 0.01205 (high sensitivity)
• Turnover: 7,309 (highly liquid)
• Leverage: 98.88% (very high)
• Payoff at 5% upside: $40.90
This contract provides maximum leverage with strong gamma exposure, making it ideal for aggressive bulls expecting a sharp move above $725. The high turnover ensures minimal slippage.

Action Alert: Aggressive bulls should consider REGN20251219C725 into a break above $725, while conservative traders may use REGN20251219C720 for a more balanced play.

Backtest Regeneron Stock Performance
The backtest of Regeneron (REGN) after a 3% intraday increase from 2022 to the present shows favorable performance metrics. The 3-day win rate is 51.72%, the 10-day win rate is 54.77%, and the 30-day win rate is 57.40%, indicating a higher probability of positive returns in the short term. The maximum return during the backtest was 1.88%, which occurred on day 54, suggesting that REGN can deliver modest gains following a 3% intraday surge.

Regeneron’s Myeloma Breakthrough: A Catalyst for Sustained Gains
Regeneron’s Lynozyfic trial data represents a transformative moment for the stock, with the potential to redefine myeloma treatment and drive long-term value. The current technical setup, including oversold RSI and bullish MACD, supports a continuation of the upward trend. Investors should closely monitor the $725 level as a critical inflection point. With Amgen (AMGN) rising 0.65%, the biotech sector is showing resilience, but Regeneron’s innovation edge positions it as a standout play. Act now: Buy REGN20251219C725 for a high-leverage bet on a breakout above $725.